Literature DB >> 11404228

Determinants of insulin-stimulated glucose disposal in middle-aged, premenopausal women.

M J Toth1, C K Sites, W T Cefalu, D E Matthews, E T Poehlman.   

Abstract

Controversy exists regarding the relative importance of adiposity, physical fitness, and physical activity in the regulation of insulin-stimulated glucose disposal. To address this issue, we measured insulin-stimulated glucose disposal [mg. kg fat-free mass (FFM)(-1). min(-1); oxidative and nonoxidative components] in 45 nondiabetic, nonobese, premenopausal women (mean +/- SD; 47 +/- 3 yr) by use of hyperinsulinemic euglycemic clamp (40 mU. m(-2). min(-1)) and [6,6-2H2]glucose dilution techniques. We also measured body composition, abdominal fat distribution, thigh muscle fat content, maximal oxygen consumption (VO2 max), and physical activity energy expenditure ((2)H(2)(18)O kinetics) as possible correlates of glucose disposal. VO2 max was the strongest correlate of glucose disposal (r = 0.63, P < 0.01), whereas whole body and abdominal adiposity showed modest associations (range of r values from -0.32 to -0.46, P < 0.05 to P < 0.01). A similar pattern of correlations was observed for nonoxidative glucose disposal. None of the variables measured correlated with oxidative glucose disposal. The relationship of VO2 max to glucose disposal persisted after statistical control for FFM, percent body fat, and intra-abdominal fat (r = 0.40, P < 0.01). In contrast, correlations of total and regional adiposity measures to insulin sensitivity were no longer significant after statistical adjustment for VO2 max. VO2 max was the only variable to enter stepwise regression models as a significant predictor of total and nonoxidative glucose disposal. Our results highlight the importance of VO2 max as a determinant of glucose disposal and suggest that it may be a stronger determinant of variation in glucose disposal than total and regional adiposity in nonobese, nondiabetic, premenopausal women.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11404228     DOI: 10.1152/ajpendo.2001.281.1.E113

Source DB:  PubMed          Journal:  Am J Physiol Endocrinol Metab        ISSN: 0193-1849            Impact factor:   4.310


  14 in total

Review 1.  Abdominal adipose tissue distribution and metabolic risk.

Authors:  Suzy Wong; Ian Janssen; Robert Ross
Journal:  Sports Med       Date:  2003       Impact factor: 11.136

2.  Increased palmitate intake: higher acylcarnitine concentrations without impaired progression of β-oxidation.

Authors:  C Lawrence Kien; Dwight E Matthews; Matthew E Poynter; Janice Y Bunn; Naomi K Fukagawa; Karen I Crain; David B Ebenstein; Emily K Tarleton; Robert D Stevens; Timothy R Koves; Deborah M Muoio
Journal:  J Lipid Res       Date:  2015-07-08       Impact factor: 5.922

3.  Relationship of androgens to body composition, energy and substrate metabolism and aerobic capacity in healthy, young women.

Authors:  Jennifer L Keller; Peter R Casson; Michael J Toth
Journal:  Steroids       Date:  2011-06-25       Impact factor: 2.668

4.  Impaired muscle protein anabolic response to insulin and amino acids in heart failure patients: relationship with markers of immune activation.

Authors:  Michael J Toth; Martin M LeWinter; Philip A Ades; Dwight E Matthews
Journal:  Clin Sci (Lond)       Date:  2010-08-17       Impact factor: 6.124

5.  Dynamic changes in fat oxidation in human primary myocytes mirror metabolic characteristics of the donor.

Authors:  Barbara Ukropcova; Michele McNeil; Olga Sereda; Lilian de Jonge; Hui Xie; George A Bray; Steven R Smith
Journal:  J Clin Invest       Date:  2005-07       Impact factor: 14.808

6.  Change of energy expenditure from physical activity is the most powerful determinant of improved insulin sensitivity in overweight patients with coronary artery disease participating in an intensive lifestyle modification program.

Authors:  Marie C Audelin; Patrick D Savage; Michael J Toth; Jean Harvey-Berino; David J Schneider; Janice Y Bunn; Maryann Ludlow; Philip A Ades
Journal:  Metabolism       Date:  2011-12-05       Impact factor: 8.694

7.  Ovarian suppression with a gonadotropin-releasing hormone agonist does not alter insulin-stimulated glucose disposal.

Authors:  Brian C Cooper; Cynthia K Sites; Peter R Casson; Michael J Toth
Journal:  Fertil Steril       Date:  2007-05       Impact factor: 7.329

8.  Phenotypic and molecular evaluation of a chromosome 1q region with linkage and association to type 2 diabetes in humans.

Authors:  Hua Wang; Nicholas P Hays; Swapan K Das; Rebekah L Craig; Winston S Chu; Neeraj Sharma; Steven C Elbein
Journal:  J Clin Endocrinol Metab       Date:  2009-01-13       Impact factor: 5.958

9.  Effect of ovarian suppression with gonadotropin-releasing hormone agonist on glucose disposal and insulin secretion.

Authors:  Michael J Toth; Brian C Cooper; Richard E Pratley; Andrea Mari; Dwight E Matthews; Peter R Casson
Journal:  Am J Physiol Endocrinol Metab       Date:  2008-04-15       Impact factor: 4.310

10.  Visceral fat and adiponectin: associations with insulin resistance are tissue-specific in women.

Authors:  Robert H Coker; Rick H Williams; Sophie E Yeo; Patrick M Kortebein; Don L Bodenner; Philip A Kern; William J Evans
Journal:  Metab Syndr Relat Disord       Date:  2009-02       Impact factor: 1.894

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.